Multiply Labs mentioned its modular method to cell remedy automation reduces manufacturing bottlenecks. | Supply: Multiply Labs
Multiply Labs Inc. right now introduced an settlement with AstraZeneca to judge the potential for making use of good manufacturing observe, or GMP-ready, robotic programs to commercial-scale cell remedy manufacturing. The collaboration will concentrate on automation of industry-standard devices utilized in cell remedy manufacturing utilizing Multiply Labs’ robotic biomanufacturing system.
The aim is to allow scalable, high-throughput manufacturing whereas sustaining the rigorous high quality and regulatory requirements required for scientific and business use.
“Cell therapies are among the many most promising, but complicated medicines being developed right now,” mentioned Fred Parietti, Ph.D., CEO of Multiply Labs. “Our mission is to make these therapies extra extensively accessible by growing manufacturing effectivity and scale.”
“This settlement with AstraZeneca permits us to judge our multi-arm robotic clusters in a setting the place we will mix a number of the world’s greatest scientific and scientific experience with our robotic platform to construct the subsequent technology of high-throughput, GMP-ready cell remedy manufacturing,” he added.
4-armed robotic maximizes pharmaceutical manufacturing
Based in 2016, Multiply Labs offers automation to the pharmaceutical {industry}. It develops cloud-controlled robotics for the manufacturing of superior therapies at scale.
The San Francisco-based company‘s latest systems use 4 robotic arms working in parallel to run a broad vary of cell remedy manufacturing devices already in use by the {industry}. It mentioned this structure minimizes the necessity for course of modifications whereas maximizing output in current services, concentrating on larger productiveness.
Multiply Labs claimed that its clients embody a number of the largest pharmaceutical producers on the earth. The corporate asserted that its experience is on the intersection of robotics and biopharma – its group consists of mechanical engineers, electrical engineers, pc scientists, software program engineers, and pharmaceutical scientists.
Multiply Labs builds accomplice community
This isn’t the primary partnership Multiply Labs has made in its efforts to automate cell remedy manufacturing. In September, it partnered with Thermo Fisher Scientific. The collaboration is specializing in integrating robots with Thermo Fisher’s automated Gibco CTS DynaCellect Magnetic Separation System.
The Gibco CTS DynaCellect System is a closed, automated isolation, activation, and bead-removal system for cell remedy growth and manufacturing. Along with fit-for-purpose consumables, it provides excessive cell purity, restoration, and viability.
By combining the Gibco CTS DynaCellect System with Multiply Labs’ robotic automation experience, the companions mentioned they hope to speed up crucial steps in cell remedy manufacturing by lowering guide intervention and bettering course of consistency.
In June, Multiply Labs announced a pilot collaboration with Kyverna Therapeutics, a clinical-stage biopharmaceutical firm centered on growing cell therapies for sufferers with autoimmune illnesses. Kyverna deliberate to judge the automation of its cell remedy manufacturing processes utilizing Multiply Labs’ robotic programs for KYV-102.
The submit Multiply Labs companions with AstraZeneca to automate cell remedy manufacturing appeared first on The Robotic Report.
